The exclusive trillion-dollar market cap club has a new member—and this time, it’s not a tech giant. Pharmaceutical leader Eli Lilly (NYSE: LLY) recently breached the $1 trillion valuation mark, becoming the first healthcare company to achieve this milestone. Previously, this rarefied space was occupied only by the “Magnificent Seven” tech stocks, oil titan Saudi Aramco, and Warren Buffett’s Berkshire Hathaway.
On November 21, Eli Lilly’s shares rose 1.7% during intraday trading, briefly pushing its market capitalization to $1 trillion. Although it closed slightly lower that day, settling around $950 billion, the stock regained its trillion-dollar status in intraday trading the following Monday. So far this year, Lilly’s share price has surged 38%, and over the past five years, it has delivered an astounding 645% return.
A major catalyst behind Lilly’s meteoric rise is the booming success of its GLP-1 drugs, particularly tirzepatide. Marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, the treatment surpassed Merck’s cancer immunotherapy drug Keytruda in the third quarter to become the world’s best-selling medication.
The GLP-1 drug market itself is expanding rapidly. Valued at approximately $52 billion in 2024, it is projected to grow to $187 billion by 2032, reflecting a compound annual growth rate of nearly 17%. Eli Lilly has captured a dominant 58% share of this high-growth market.
In Q3, sales of Mounjaro and Zepbound reached a combined $10.1 billion, driving the company’s total revenue to $17.6 billion—a 54% year-over-year increase. Earnings per share also saw a dramatic jump, rising from $1.07 to $6.21.
Beyond its current drug portfolio, several recent developments have bolstered investor optimism:
Despite trading at a premium—with a P/E ratio of 52—Eli Lilly’s growth trajectory remains compelling. Since 2019, the number of U.S. patients starting GLP-1 treatments for non-diabetes purposes has skyrocketed by 700%.
The company is expected to generate $75.3 billion in revenue next year, a 26% increase from the last twelve months. Based on a forward price-to-sales ratio of 14.1, its market cap could reach $1.06 trillion by the end of 2026.
To support this growth, Eli Lilly is aggressively expanding manufacturing capacity, with new facilities underway in Virginia, Texas, and Puerto Rico. It is also investing in AI-driven drug discovery through a recently announced partnership with NVIDIA. The company’s pipeline includes promising therapies for ulcerative colitis, Alzheimer’s, cancer, and skin conditions.
With its leading position in the diabetes and obesity markets, key government agreements improving drug access, a promising oral drug launch ahead, and a deep R&D pipeline, Eli Lilly stands as a unique blend of stability and high growth. For investors with available capital and a long-term view, the pharmaceutical giant continues to present a compelling opportunity.
